MedPath

D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement

Completed
Conditions
Heart Valve Disease
Interventions
Registration Number
NCT01996657
Lead Sponsor
Wuhan Asia Heart Hospital
Brief Summary

The optimal intensity of oral anticoagulation in China patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in Chinese patients. Elevated D-dimer could reflect a pro-thrombogenic or prothrombotic state, and thus might be used to decide the intensity of oral anticoagulation.

This study was to evaluate whether elevated D-dimer levels could help to determine the intensity of oral anticoagulation in patients with mechanical heart valve prostheses.

Detailed Description

Background: The optimal intensity of oral anticoagulation in China patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in Chinese patients. Elevated D-dimer could reflect a pro-thrombogenic or prothrombotic state, and thus might be used to decide the intensity of oral anticoagulation.

Objective: This study was to evaluate whether elevated D-dimer levels could help to determine the intensity of oral anticoagulation in patients with mechanical heart valve prostheses.

Methods: A single-center, prospective study was performed. 748 Patients with mechanical valve replacement who had received oral anticoagulation. The patients were randomly assigned to three groups The intensity of anticoagulation for group one was standard intensity (INR:2.5-3.5). The intensity of anticoagulation for group two was kept at low intensity without adjustment (INR:1.8-2.6), and for group three , The intensity of anticoagulation maintained at low level initiatively (INR:1.8-2.6), D-dimer testing were analyzed two times at 3 month later. In case of D-dimer level elevated, adjusted the intensity of anticoagulation to standard level. The endpoint of the study was the subsequent thromboembolic and major bleeding during an average follow-up of 2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
772
Inclusion Criteria
  1. age>18years,male or female without pregnancy;
  2. Suffered the mechanical valves replacement in Wuhan Asia Heart Hospital;
  3. The operation type was Mitral valve replacement or Double valves replacement(aortic and mitral valve replacement).
Exclusion Criteria

Patients with following diseases within 3 months.

  1. deep venous thromboembolism
  2. Pulmonary embolism
  3. Aortic dissection
  4. stroke
  5. Cerebral hemorrhage
  6. Myocardial infarction

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Standard intensity of anticoagulationWarfarinAfter mechanical valve replacement,patients should be gave oral anticoagulants,such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Low intensity and adjusted by elevated D-dimerWarfarinThe intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Low intensity without adjustmentWarfarinThe intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Primary Outcome Measures
NameTimeMethod
Thrombotic Events24 months

The thrombotic events included valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism, and myocardial infarction.

Bleeding Events;Up to 24 months

The bleeding events included cerebral hemorrhage, gastrointestinal bleeding and other major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. vision loss) or necessitates transfusion.

Secondary Outcome Measures
NameTimeMethod
All Cause DeathsUp to 24 months

The deaths from all causes

Trial Locations

Locations (2)

Wuhan Asia Heart Hospital

🇨🇳

Wuhan, Hubei, China

WAHH

🇨🇳

Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath